MARKET

BTAI

BTAI

BIOXCEL THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.16
-1.33
-2.49%
Pre Market 08:00 07/06 EDT
OPEN
54.41
PREV CLOSE
53.49
HIGH
54.84
LOW
51.57
VOLUME
333.15K
TURNOVER
--
52 WEEK HIGH
61.50
52 WEEK LOW
3.760
MARKET CAP
1.05B
P/E (TTM)
-22.1279
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BTAI stock price target is 84.25 with a high estimate of 150.00 and a low estimate of 53.00.

EPS

BTAI News

More
Hedge Funds Are Warming Up To BioXcel Therapeutics, Inc. (BTAI)
Insider Monkey · 10h ago
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
BioXcel Therapeutics (BTAI) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/23 20:12
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
GlobeNewswire · 06/23 12:00
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
2 Stocks I�d Avoid at All Costs
MotleyFool.com · 06/18 10:55
3 Strong Buy Pharmaceutical Stocks With Major Catalysts Approaching
TipRanks · 06/17 14:43
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About BTAI

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.
More

Webull offers kinds of BioXcel Therapeutics Inc stock information, including NASDAQ:BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.